China Universal Asset Management Co. Ltd. Takes Position in Takeda Pharmaceutical Co. $TAK

Key Points

• China Universal Asset Management bought a new position of 64,000 shares (~$998,000) in Takeda during the fourth quarter, signaling recent institutional buying interest.
• Analyst sentiment has improved recently—Morgan Stanley initiated coverage with an "overweight" rating and Sanford C. Bernstein and Wall Street Zen upgraded their views—leaving a consensus rating of "Moderate Buy" (2 Buy, 2 Hold).
• Takeda missed Q4 estimates (EPS $0.48 vs. $0.55 consensus; revenue $7.60B vs. $7.81B) but set FY2025 guidance at 3.160 EPS; the stock trades near $16.65 with a market cap around $53B and a P/E of ~69.

China Universal Asset Management Co. Ltd. bought a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 64,000 shares of the company's stock, valued at approximately $998,000.

Other large investors have also added to or reduced their stakes in the company. Private Trust Co. NA lifted its holdings in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. True Wealth Design LLC boosted its position in Takeda Pharmaceutical by 1,262.3% during the third quarter. True Wealth Design LLC now owns 2,711 shares of the company's stock worth $40,000 after purchasing an additional 2,512 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Takeda Pharmaceutical in the third quarter valued at about $74,000. Finally, Farther Finance Advisors LLC raised its position in shares of Takeda Pharmaceutical by 24.5% in the third quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company's stock valued at $102,000 after purchasing an additional 1,378 shares during the period. Institutional investors own 9.17% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an "overweight" rating for the company. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a "market perform" rating to an "outperform" rating in a report on Wednesday, April 8th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, April 11th. Weiss Ratings restated a "hold (c-)" rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Finally, Zacks Research raised Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy".

Takeda Pharmaceutical Stock Down 0.0%

TAK opened at $16.65 on Friday. The stock has a fifty day moving average of $18.10 and a 200-day moving average of $16.17. The company has a market capitalization of $52.97 billion, a P/E ratio of 69.36 and a beta of -0.01. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Friday, January 30th. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.07). Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The business had revenue of $7.60 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. On average, equities analysts expect that Takeda Pharmaceutical Co. will post 1.57 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.